BCAX

Conviction 100HealthcareScan · Thu, Jun 25, 2026

Shooting star

BCAX$26.34+2.73%

ResistanceSupportVol 14Insider sell

Vol MA14 905.82K

Mar 26Apr 14May 1May 19Jun 8Jun 25

Bicara Therapeutics Inc.PHARMACEUTICAL PREPARATIONSwww.bicara.com ↗

Price26.34

Change+2.73%

Gap+0.23%

Rel volume6.23×

Avg volume799.26K

Avg $ vol18.5M

SMA 2021.96

SMA 5022.08

SMA 20018.14

Price vs 50+19.31%

Price vs 200+45.19%

MA stackbullish

50/200 cross—

Supertrendup · 22.56

RSI (14)76

MACD hist0.60

MACD crossbull · 9d

Stoch %K / %D81 / 86

ADX (14)22

+DI / −DI37 / 10

RSI divergence—

MACD divergence—

ATR %+5.03%

ADR %5.45%

52w high26.34

52w low8.71

From 52w high+0.00%

Above 52w low+202.41%

New 52w highYes

SqueezeOff

Bollinger width35.91%

%B1.06

Donchian pos81.92%

Donchian high27.94

Donchian low19.09

AVWAP (52w high)26.63

vs AVWAP high-1.10%

AVWAP (52w low)17.25

vs AVWAP low+52.65%

OBV trendUp

Chaikin MF (20)0.02

Today vs 20d6.23×

Avg vol (14d)905.82K

Avg vol (20d)799.26K

Avg $ vol (20d)18.5M

Market cap1.73B

RS 3m (vs SPY)+28.93%

RS 6m (vs SPY)+37.95%

RS line new highYes

Trend template8/8

Technical rank92.9

1 week+14.92%

1 month+19.84%

3 months+41.01%

6 months+43.78%

1 year+176.97%

YTD+60.81%

P/E-12.55

P/B3.37

P/S—

P/FCF-16.16

EPS-2.52

Div yield—

ROE-26.84%

ROA-24.92%

Debt/Eq—

Current13.85

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth-102.88%

Price target32.11

Target upside21.91%

Analyst ratingBuy

Institutional108.19%

Ent. value1.41B

Revenue—

Net income-56.21M

Gross profit—

Free cash flow-107.11M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out65.7M

Employees103

ListedFri, Sep 13, 2024

Free float29.77M

Float %47.0%

Short interest10.08M

Days to cover22.5d

Short volume40.2%

Squeeze score80 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.93 vs −$0.64

Last surprise-45.3% miss

Setup gradeA+

Conviction100 / 100

Pattern quality—

Tech rank92.9 / 100

Group rank50 / 100

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmShooting star

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in BCAX

All disclosures →

No recent disclosed trades by Congress in BCAX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in BCAX · 10 buys

Insider	Side	Shares	Value	Traded	Filed
Robertson Scott M. Director · Stock Option (Right to Buy) · 2026-06-09	Grant	19.48K	$0	2026-06-09	2026-06-10
Simson Jake Director · Stock Option (Right to Buy) · 2026-06-09	Grant	19.48K	$0	2026-06-09	2026-06-10
POWELL MICHAEL Director · Stock Option (Right to Buy) · 2026-06-09	Grant	19.48K	$0	2026-06-09	2026-06-10
Haviland Kate Director · Stock Option (Right to Buy) · 2026-06-09	Grant	19.48K	$0	2026-06-09	2026-06-10
RA CAPITAL MANAGEMENT, L.P. Director · Stock Option (Right to Buy) · 2026-06-09	Grant	19.48K	$0	2026-06-09	2026-06-10
Shah Rajeev M. Director · Stock Option (Right to Buy) · 2026-06-09	Grant	19.48K	$0	2026-06-09	2026-06-10
Kolchinsky Peter Director · Stock Option (Right to Buy) · 2026-06-09	Grant	19.48K	$0	2026-06-09	2026-06-10
Bowden Christopher Director · Stock Option (Right to Buy) · 2026-06-09	Grant	19.48K	$0	2026-06-09	2026-06-10
RA Capital Nexus Fund III, L.P. Director · Stock Option (Right to Buy) · 2026-06-09	Grant	19.48K	$0	2026-06-09	2026-06-10
Mazumdar-Shaw Kiran Director · Stock Option (Right to Buy) · 2026-06-09	Grant	19.48K	$0	2026-06-09	2026-06-10

SEC filings

EDGAR filings in BCAX · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.